Citation Impact
Citing Papers
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
2008
Complement and microglia mediate early synapse loss in Alzheimer mouse models
2016 StandoutScience
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
2013 StandoutScience
A Novel Lung Metastasis Signature Links Wnt Signaling with Cancer Cell Self-Renewal and Epithelial-Mesenchymal Transition in Basal-like Breast Cancer
2009
Jinx , an MCMV susceptibility phenotype caused by disruption of Unc13d : a mouse model of type 3 familial hemophagocytic lymphohistiocytosis
2007 StandoutNobel
A small-molecule switch for Golgi sulfotransferases
2004 StandoutNobel
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
2010 StandoutScience
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities
2008
Genetic variation at the 8q24.21 renal cancer susceptibility locus affects HIF binding to a MYC enhancer
2016 StandoutNobel
MEK1/2 inhibitors in the treatment of gynecologic malignancies
2014
Clinical implications of using molecular diagnostics for ovarian cancers
2013
Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma
2013
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
2009 Standout
Guilty as charged
2004
TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity
2007 StandoutNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Apoptosis by Death Factor
1997 Standout
BRAF Mutation is associated with early stage disease and improved outcome in patients with low‐grade serous ovarian cancer
2012
Development of Lupus-like Autoimmune Diseases by Disruption of the PD-1 Gene Encoding an ITIM Motif-Carrying Immunoreceptor
1999 StandoutNobel
B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events.
1996
Gene expression profiling of the tumor microenvironment during breast cancer progression
2009
Molecular mechanisms of resistance and toxicity associated with platinating agents
2006 Standout
Homeostatic regulation of CD8+ T cells by perforin
1999
Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study
2012
In ovarian neoplasms, BRAF , but not KRAS , mutations are restricted to low‐grade serous tumours
2004
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
2010 StandoutNature
Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF
2004 Standout
Metagenomic biomarker discovery and explanation
2011 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
BRAF Mutation in Papillary Thyroid Carcinoma
2003
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
Origins and molecular pathology of ovarian cancer
2005
Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis?
2004
Systemic Lupus Erythematosus
2011 Standout
Endometrial carcinoma: controversies in histopathological assessment of grade and tumour cell type
2010
Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer
2007 Standout
The Classical Complement Cascade Mediates CNS Synapse Elimination
2007 Standout
Oncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
2008 Standout
Stochastic State Transitions Give Rise to Phenotypic Equilibrium in Populations of Cancer Cells
2011 Standout
Signalling Pathways Implicated in Early Mammary Gland Morphogenesis and Breast Cancer
2006
Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization
1996
Self-Tolerance Checkpoints in B Lymphocyte Development
1995
The Fas Death Factor
1995 StandoutScience
WNT signaling enhances breast cancer cell motility and blockade of the WNT pathway by sFRP1 suppresses MDA-MB-231 xenograft growth
2009
Clonal selection and learning in the antibody system
1996 StandoutNature
Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies
1998 Standout
Fas and FasL in the homeostatic regulation of immune responses
1995 StandoutNobel
Ovarian Tumorigenesis
2004
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
2010 Standout
The role of senescent cells in ageing
2014 StandoutNature
Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma
2015
Points of control in inflammation
2002 StandoutNature
Targeting the mitogen-activated protein kinase cascade to treat cancer
2004
CD95 (Fas)-dependent elimination of self-reactive B cells upon interaction with CD4+T cells
1995 Nature
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Ras, PI(3)K and mTOR signalling controls tumour cell growth
2006 StandoutNature
Chromatin–IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors
2002 StandoutNature
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
2012
The fas antigen is involved in peripheral but not thymic deletion of T lymphocytes in T cell receptor transgenic mice
1994
Role of YAP/TAZ in mechanotransduction
2011 StandoutNature
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
2009
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
2009 Standout
Activation-induced death of mature T cells in the regulation of immune responses
1995
WNT/β-catenin mediates radiation resistance of mouse mammary progenitor cells
2007
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Repression of B7.2 on Self-reactive B Cells Is Essential to Prevent Proliferation and Allow Fas-mediated Deletion by CD4+ T Cells
1998 StandoutNobel
Naturally Arising CD4+Regulatory T Cells for Immunologic Self -Tolerance and Negative Control of Immune Responses
2003 StandoutNobel
TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor
1997 StandoutNobel
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.
2003
Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids.
1995
Fas ligand mediates activation-induced cell death in human T lymphocytes.
1995 StandoutNobel
The MAPK pathway across different malignancies: A new perspective
2014 Standout
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
1997 Standout
Activity of Sorafenib in Recurrent Ovarian Cancer and Primary Peritoneal Carcinomatosis: A Gynecologic Oncology Group Trial
2010
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors
2013
Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege
1995 StandoutScience
Ovarian Cancer
2008
Apoptosis in the Pathogenesis and Treatment of Disease
1995 StandoutScience
Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon
2005
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Mutations of BRAF and KRAS Precede the Development of Ovarian Serous Borderline Tumors
2004
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Harboring BRAF Mutations
2011
High Levels of a Major Histocompatibility Complex II–Self Peptide Complex on Dendritic Cells from the T Cell Areas of Lymph Nodes
1997 StandoutNobel
Tubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage
1992 Standout
Cross-linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-gamma and tumor necrosis factor- alpha secretion
1994
Immunological Memory and Protective Immunity: Understanding Their Relation
1996 StandoutScience
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
2004 Standout
The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis
2006
Works of Gad Singer being referenced
Mutational Analysis of K-ras Segregates Ovarian Serous Carcinomas into Two Types: Invasive MPSC (Low-grade Tumor) and Conventional Serous Carcinoma (High-grade Tumor)
2003
Diverse Tumorigenic Pathways in Ovarian Serous Carcinoma
2002
Different types of microsatellite instability in ovarian carcinoma
2004
Patterns of p53 Mutations Separate Ovarian Serous Borderline Tumors and Low- and High-grade Carcinomas and Provide Support for a New Model of Ovarian Carcinogenesis
2005
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
2003
Mature CD4+ T lymphocytes from MRL/lpr mice are resistant to receptor-mediated tolerance and apoptosis.
1993
HLA-G is a potential tumor marker in malignant ascites.
2003
Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors
2004
Renal tubular cell expression of MHC class II (I-Eb) is insufficient to initiate immune injury in a transgenic kidney transplant model.
1993
Dexamethasone prevents autoimmune nephritis and reduces renal expression of Ia but not costimulatory signals.
1992